Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

SUMMARY: Romosozumab, which binds sclerostin, rebuilds the skeletal foundation before transitioning to antiresorptive treatment. This subgroup analysis of an international, randomized, double-blind study in postmenopausal women with osteoporosis showed efficacy and safety outcomes for romosozumab fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyauchi, Akimitsu, Dinavahi, Rajani V., Crittenden, Daria B., Yang, Wenjing, Maddox, Judy C., Hamaya, Etsuro, Nakamura, Yoichi, Libanati, Cesar, Grauer, Andreas, Shimauchi, Junichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551345/
https://www.ncbi.nlm.nih.gov/pubmed/31168657
http://dx.doi.org/10.1007/s11657-019-0608-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551345/
https://www.ncbi.nlm.nih.gov/pubmed/31168657
http://dx.doi.org/10.1007/s11657-019-0608-z

Ejemplares similares